The Memory Disorders Programs at Johns Hopkins provide comprehensive, compassionate and timely diagnosis and treatment to people with a variety of memory disorders. 我们关心护理的各个方面, from diagnosis and treatment to improving care and developing new therapies through research in brain imaging and laboratory studies. 我们的团队包括神经病学专家, 精神病学和老年医学, 谁密切合作，提供最先进的护理. Our mission is to improve the lives of patients living with memory disorders.
我们的专业项目
There are several clinical programs at The Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center dedicated to diagnosis and treatment of memory disorders. Each program is led by an outstanding clinician with many years of experience in clinical care.
我们治疗的记忆相关疾病
造成记忆障碍的原因有很多. Some develop suddenly and stay the same over time, while others progress. 这些疾病在50年前是无法治愈的. Now some treatments are available and better ones are on the horizon. 在我们的健康部分了解有关这些疾病的更多信息:
痴呆
- 阿尔茨海默病
- 路易体痴呆(DLB)
- 额颞叶痴呆(FTD)
- 艾滋病痴呆
- 轻度认知障碍(MCI)
- 与以下疾病相关的痴呆症 常压脑积水(NPH)
- 血管性痴呆
失忆
- 健忘综合征
- 短暂性全局遗忘(TGA)
我们的团队
彼得V. 拉宾,M.D.
精神病学和行为科学教授
研究领域
Our research program in memory disorders seeks to improve understanding of the basic mechanisms of disease and accelerate early diagnosis, so that novel treatments can be implemented at the point in the disease process when they are most likely to be effective. We also seek to understand more about modifiable health and life-style changes that influence risk for disease. Our researchers also conduct clinical trials of some of the most promising strategies.
-
主要调查人员: 黄志强博士.D., 李彤博士.D.
The goal of this project is to characterize a recently developed mouse model that not only exhibits amyloid β (Aβ) amyloidosis and tauopathy, 但也表现出强烈的年龄依赖性神经元丧失. This new mouse model will be used to test the overarching hypothesis that Aβ induces tau aggregation, which in turn initiates synaptic dysfunction and promotes neuronal loss. The research team hopes is that such a model system will provide the opportunity to evaluate Aβ amyloidosis and tauopathy dependent loss of neurons as the principal outcome measure in preclinical testing of mechanism-based therapies, such as those designed to target tauopathy and/or Aβ amyloidosis.
欲了解更多信息，请联系Dr. 菲利普王 (电子邮件保护). -
首席研究员: Alena Savonenko M.D., Ph.D.
Transgenic mouse models of amyloidosis can be used to examine the impact of treatment associated with varying levels of amyloid deposition. This project uses TetOffAPP mice in which the expression of mutant amyloid precursor protein (APP) is controlled by a tetracycline-regulated promoter. A-beta production can be suppressed in these mice with doxycycline. The goal of this project is: (1) To determine if the cognitive impairments observed in these mouse models be reversed with suppression of A-beta generation. (2) To determine whether recovery of synaptic damage is associated with cognitive improvement after A-beta production is reduced. (3) Aim 3: To examine the role of monoamine systems in relation to the degree of cognitive recovery observed after reduction of A-beta production. 集体, outcomes from these studies will address an important issue regarding the value of an anti-amyloid therapeutic strategy for AD by assessing the magnitude of functional repair and recovery after synaptic damage by A-beta.
欲了解更多信息，请联系Alena Savonenko (电子邮件保护). -
首席研究员: 约瑟夫·考雷什，医学博士.D.
The goal of this study is to determine if late-life cognitive impairment and dementia are associated with midlife vascular risk factors. 这是一个多学科的研究, 多中心前瞻性研究15例,黑白的, 男人和女人, 谁在1987年第一次接受检查时年龄在45-64岁之间. The study emphasizes the impact of mid-life vascular risks on subsequent mild cognitive impairment (MCI) and dementia because of the potential that risk-modification may lower the prevalence of MCI or dementia in late life.
欲了解更多信息，请联系Joseph Coresh (电子邮件保护). -
首席研究员: 玛丽莲年代. 艾伯特,Ph值.D.
The goal of this study is to identify predictors of cognitive decline among normal individuals. The domains of investigation being examined include: clinical and cognitive assessments, 磁共振成像, 淀粉样蛋白成像, 脑脊液和血液. 主要的问题是这些领域的度量是否, 单独或联合使用, 参与者为中年人时获得, can predict which normal individuals will develop cognitive decline over time.
欲了解更多信息，请联系Marilyn Albert (电子邮件保护). -
首席研究员: Peter van Zijl博士.D.
The goal of this study is to determine if it is possible to see amyloid plaques in the brains of patients with Alzheimer’s disease, 使用7特斯拉磁共振成像扫描仪. It is hypothesized that this high field strength will make it possible to image amyloid plaques because of magnetic susceptibility effects caused by the presence of iron in the plaques.
欲了解更多信息，请联系Sydney Feagen (电子邮件保护).
推荐十大正规网赌平台资源
Note: you are being directed to a website outside of 约翰霍普金斯医学院. Johns Hopkins is not responsible for any aspect of the external website.